Helal, Christopher J.; Sanner, Mark A.; Cooper, Christopher B.; Gant, Thomas; Adam, Mavis; Lucas, John C.; Kang, Zhijun; Kupchinsky, Stanley; Ahlijanian, Michael K.; Tate, Bonnie; Menniti, Frank S.; Kelly, Kristin; Peterson, Marcia published the artcile< Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease>, Recommanded Product: 5-Isopropylthiazol-2-amine, the main research area is cyclin dependent kinase inhibitor thiazolyl isobutyramide structure.
High-throughput screening with cyclin-dependent kinase 5 (cdk5)/p25 led to the discovery of N-(5-isopropyl-thiazol-2-yl)isobutyramide. This compound is an equipotent inhibitor of cdk5 and cyclin-dependent kinase 2 (cdk2)/cyclin E (IC50 = ca. 320 nM). Parallel and directed synthesis techniques were utilized to explore the SAR of this series. Up to 60-fold improvements in potency at cdk5 and 12-fold selectivity over cdk2 were achieved.
Bioorganic & Medicinal Chemistry Letters published new progress about Alzheimer disease. 101080-15-3 belongs to class thiazole, and the molecular formula is C6H10N2S, Recommanded Product: 5-Isopropylthiazol-2-amine.
Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica